主要从事临床药理学相关研究，现为中国抗癌协会青年理事，浙江省卫生创新高层次人才医坛新秀培养对象，临床药学中心后备学科带头人，浙江省内分泌腺体疾病诊治研究重点实验室临床药学方向学科带头人。 目前已主持国家自然科学基金、浙江省自然科学基金、浙江省中医药管理局重点项目等各类课题10项，负责拟上市药物临床试验3项，发表论文50余篇，其中第一作者/通讯作者论文25篇，参编著作1部，申请专利5项。 ·工作邮箱：zhangyiwen@hmc.edu.cn ·联系电话：13868172840

 

·进修访问：2025 年3 月–2025 年4 月，美国City of Hope研究中心，临床研究；

·进修访问：2015 年4 月–2015 年7 月，北京大学药学院，定量药理学； 

·博士：2010 年9 月–2014 年6 月，中南大学湘雅医学院，临床药理学，导师：周宏灏院士； 

·硕士：2007 年9 月–2010 年6 月，沈阳药科大学，天然药物化学，导师：吴立军教授； 

·学士：2003 年9 月–2007 年6 月，浙江中医药大学，中药学。                         

 

 ·2020 年1 月-至今，浙江省人民医院，药学部/临床研究机构办公室，副主任；
·2014 年9 月-2019 年12 月，中国科学院大学附属肿瘤医院，药剂科，临床药师。
                   

 

2020 年，浙江省卫生高层次人才医坛新秀培养对象。
                   

 

·中国抗癌协会青年理事；

·中国药理学会药物基因组学专委会常务委员 

·中国抗癌协会临床药理专委会委员； 

·中国药理学会化疗药理专业委员会青年委员； 

·中国药理学会治疗药物监测研究专业委员会青年委员； 

·浙江省转化医学会临床试验分会副会长； 

·浙江省医学会临床药学分会委员； 

·浙江省医学会临床试验与伦理分会委员；

·浙江省药学会专业委员会药物毒理专委会委员； 

·《中国现代应用药学杂志》青年编委； 

·《American Journal of Health-System Pharmacy》（中文版）青年编委。
                   

 

1. 国家自然科学基金面上项目，雄激素受体对头颈鳞癌发生发展中性别偏倚的调控机制及干预策略研究，2025年1月-2028年12月，资助金额 48万，主持； 

2. 浙江省科技厅“尖兵”“领雁”研发攻关项目，重大疑难疾病的中医药诊疗关键技术研究-中医“症-证-诊-方”四位一体的肺纤维化全程诊疗策略开发及循证评价研究，2024年1月-2026年12月，资助金额 290万，主持；

3. 浙江省中医药科技计划重点项目，浙产中药小春花治疗非小细胞肺癌的作用研究及制剂开发，2021 年1 月-2023 年12 月，资助金额 15万，主持；

4. 浙江省自然科学基金面上项目，肿瘤相关成纤维细胞释放外泌体传递lncRNA NEAT1 介导肝癌索拉非尼耐药的机制研究，2020 年1 月-2022 年12 月，资助金额 9万，主持；

5. 国家自然科学基金青年项目，冬凌草甲素调控PXR-CYP3A4 通路介导的胆汁淤积性肝损伤保护作用的研究，2016 年1 月-2018 年12 月，资助金额 21万，主持；

6. 浙江省医药卫生科技平台面上项目，CAFs 传递外泌体调控肝癌细胞干性指数介导索拉非尼耐药的机制研究，2021 年1 月-2023 年12 月，资助金额 3万，主持；

7. 浙江省医药卫生科技平台青年人才项目，丹皮酚调控LOX-1 信号通路抑制乳腺癌MCF-7 细胞转移作用研究，2017 年1 月-2019 年12 月，资助金额 3万，主持；

8. 浙江省中医药科技计划，川芎嗪对肝药物代谢酶CYP3A4 的影响及机制研究，2016 年1 月-2018 年12 月，资助金额 3万，主持。    

       

 

1. Song F, Yi X, Zheng X, Zhang Z, Zhao L, Shen Y, Zhi Y, Liu T, Liu X, Xu T, Hu X, Zhang Yiwen*, Shou H*, Huang P*. Zebrafish patient-derived xenograft system for predicting carboplatin resistance and metastasis of ovarian cancer. Drug Resist Updat. 2025 Jan;78:101162.

2. Lin S, Lou Y, Hao R, Shao Y, Yu J, Fang L, Bao M, Yi W, Zhang Yiwen. A single-dose, randomized, open-label, four-period, crossover equivalence trial comparing the clinical similarity of the proposed biosimilar rupatadine fumarate to reference Wystamm? in healthy Chinese subjects. Front Pharmacol. 2024 May 17;15:1328142.

3. Lou Y, Zou X, Pan Z, Huang Z, Zheng S, Zheng X, Yang X, Bao M, Zhang Y, Gu J, Zhang Yiwen. The mechanism of action of Botrychium (Thunb.) Sw. for prevention of idiopathic pulmonary fibrosis based on 1H-NMR-based metabolomics. J Pharm Pharmacol. 2024 Aug 2;76(8):1018-1027.

4. Song Feifeng, Zhang Zhentao, Liu W, Xu T, Hu X, Wang Q, Zhang W, Ge L, Zhang C, Hu Q, Qin H, Zhang S, Ren X, Fan W, Zhang Yiwen*, Huang Ping*. Peptide Transporter 1-Mediated Dipeptide Transport Promotes Hepatocellular Carcinoma Metastasis by Activating MAP4K4/G3BP2 Signaling Axis. Adv Sci (Weinh). 2024 Apr 19:e2306671.

5. Lou Yutao, Cheng Mengting, Cao Qin, Li Kening, Qin Hui, Bao Meihua, Zhang Yuan, Lin Sisi, Zhang Yiwen. Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder. J Pharm Biomed Anal. 2024 Mar 15;240:115937.

6. Hao R, Shao Y, Lin S, Wu Y, Bian L, Zhang Yiwen. Bioequivalence Study of Tebipenem Pivoxil in Healthy Chinese Adults. Drugs R D. 2024 Mar;24(1):89-96. 

7. Zhang Yiwen^#, Lu Lu^#, Song Feifeng, Zou Xiaozhou, Liu Yujia, Zheng Xiaowei, Qian Jing, Gu Chunyan, Huang Ping, Yang Ye. Research progress on non-protein-targeted drugs for cancer therapy. J Exp Clin Cancer Res. 2023 Mar 14;42(1):62.  ISSN: 1756-9966

8. Lou Yutao, Song Feifeng, Cheng Mengting, Hu Ying, Chai Yitao, Hu Qing, Wang Qiyue, Zhou Hongying, Bao Meihua, Gu Jinping, Zhang Yiwen. Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats. PeerJ. 2023 Aug 10;11:e15844.

9. Lou Yutao, Sun Zhiyong, Chai Yitao, Qin Hui, Hu Qing, Liu Yujia, Zheng Xiaowei, Hu Ying, Bao Meihua, Gu Jinping, Zhang Yiwen. Simultaneous quantification of donafenib, sorafenib, and their N-oxide metabolites in rat plasma using a HPLC-MS/MS method. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Sep 1;1229:123871. 

10. Liu Yujia, Wang Jiafeng, Hu X, Pan Zongfu, Xu Tong, Xu Jiajie, Jiang Liehao, Huang Ping, Zhang Yiwen^*, Ge Minghua^*. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy. Drug Resist Updat. 2023 May;68:100939.

11. Sun Zhiyong, Zou Xiaozhou, Bao M, Huang Zhongjie, Lou Yutao, Zhang Yiwen^*, Huang Ping^*. Role of ferroptosis in fibrosis diseases. Am J Med Sci. 2023 Aug;366(2):87-95.

12. Sun Zhiyong, Lou Yutao, Hu Xiaoping, Song Feifeng, Zheng Xiaowei, Hu Ying, Ding Haiying, Zhang Yiwen^*, Huang Ping^*. Single-cell sequencing analysis fibrosis provides insights into the pathobiological cell types and cytokines of radiation-induced pulmonary fibrosis. BMC Pulm Med. 2023 Apr 28;23(1):149.

13. Zou Xiaozhou, Liu Ting, Huang Zhongjie, Zhou Wei, Yuan Mengnan, Zhao Hongying, Pan Zongfu, Chen Pengcheng, Shao Yanfei, Hu Xiaoping, Zhang Su, Zheng Shuilian, Zhang Yiwen^*, Huang Ping^*. SOX17 is a Critical Factor in Maintaining Endothelial Function in Pulmonary Hypertension by an Exosome-Mediated Autocrine Manner. Adv Sci (Weinh). 2023 May;10(14):e2206139. 

14. Song Feifeng^#, Zhang Yiwen^#, Pan Zongfu, Hu Xiaoping, Yi Y, Zheng Xiaowei, Wei H, Huang Ping. Identification of novel key genes associated with the metastasis of prostate cancer based on bioinformatics prediction and validation. Cancer Cell Int. 2021 Oct 25;21(1):559.

15. Qin H^#, Zhang Yiwen^#, Lou Yutao, Pan Zongfu, Song Feifeng, Liu Yujia, Xu Tong, Zheng Xiaowei, Hu Xiaoping, Huang Ping. Overview of PROTACs Targeting the Estrogen Receptor: Achievements for Biological and Drug Discovery. Curr Med Chem. 2022;29(22):3922-3944.

16. Song Feifeng^#, Zhang Yiwen^#, Pan Zongfu, Hu Xiaoping, Zhang Qi, Huang Fang, Ye Xiaolan, Huang Ping. The role of alcohol dehydrogenase 1C in regulating inflammatory responses in ulcerative colitis. Biochem Pharmacol. 2021 Oct;192:114691.

17. Guo Dandan, Liu Yujia, Jiang Yuchen, Zheng Shuilian, Xu Tong, Zhu Jiazhen, Chen Pengcheng, Huang Ping, Zhang Yiwen. A narrative review of the emerging role of lymphocyte antigen 6 complex locus K in cancer: from basic research to clinical practice. Ann Transl Med. 2022 Jan;10(1):26.

18. Jiang Yuchen, Song Feifeng, Hu Xiaoping, Guo Dandan, Liu Yujia, Wang Jiafeng, Jiang Liehao, Huang Ping, Zhang Yiwen. Analysis of dynamic molecular networks: the progression from colorectal adenoma to cancer. J Gastrointest Oncol. 2021 Dec;12(6):2823-2837.

19. Lou Yutao, Qin Hui, Hu Qing, Chai Yitao, Zhou Hongying, Chen Mengting, Wang Qiyue, Huang Ping, Gu Jinping, Zhang Yiwen. Development and validation of a novel LC-MS/MS method for simultaneous quantitative determination of tyrosine kinase inhibitors in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Oct 1;1208:123394.

20. Wang Qiyue, Tan Zuo, Zheng Chuanming, Wang Jiafeng, Zheng Guowan, Huang Ping, Zhang Yiwen^*, Ge Minghua^*. Number of Positive Lymph Nodes Combined with the Logarithmic Ratio of Positive Lymph Nodes predicts Survival in Patients with Non-Metastatic Larynx Squamous Cell Carcinoma. J Cancer. 2022 Mar 14;13(6):1773-1784.

21. Liu Yujia^#, Zhang Yiwen^#, Zheng Shuilian, Zheng Xiaochun, Ding Haiying, Xin Wenxiu, Sun Jiao, Li Li, Huang Ping. Botrychium schaffneri Underw. extract acts via DIABLO to induce apoptosis and inhibit proliferation of non-small cell lung carcinoma in vitro and in vivo. Ann Transl Med. 2021 Nov;9(22):1676.

22. Zirui Wan, Lifang Guo, Pengfei Li, Zhixia Zhao, Benshan Xu, Lulu Ren, Yan Yan, He Liu, Yiwen Zhang*, Liu Lihong*. Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: A pharmacogenomic study of cytochrome p450 enzymes and transporters. Journal of Clinical Pharmacy and Therapeutics, 2020, 45(5): 1159-1167.

23. Yiwen Zhang#, Xiaowei Zheng#, Yujia Liu, Luo Fang, Zongfu Pan, Meihua Bao, Ping Huang*. Effect of Oridonin on Cytochrome P450 Expression and Activities in HepaRG Cell. Pharmacology, 2018, 101(1): 246–254.

24. Xiaowei Zheng#, Yiwen Zhang#, Yujia Liu#, Luo Fang, Li Li, Jiao Sun, Zongfu Pan, Wenxiu Xin, Ping Huang*. HIF-2α activated lncRNA NEAT1 promotes hepatocellular carcinoma cell invasion and metastasis by affecting the epithelial-mesenchymal transition. Journal of Cellular Biochemistry, 2018, 119(4): 3247-3256.

25. Yiwen Zhang, Meihua Bao, Lei Hu, Qiang Qu, Honghao Zhou*. Dose-response of oridonin on hepatic cytochromes P450 mRNA expression and activities in mice. Journal of Ethnopharmacology, 2014, 155(1): 714-720.

26. Yiwen Zhang, Meihua Bao, Guo Wang, Qiang Qu, Honghao Zhou*. Induction of Human CYP3A4 by Huperzine A, Ligustrazine and Oridonin through Pregnane X Receptor-mediated Pathways. Pharmzie, 2014, 69(7): 532-536.

27. Meihua Bao#, Yiwen Zhang#, Xiaoya Lou, Yan Xiao, Yu Cheng, Honghao Zhou*. Puerarin protects endothelial cells from oxidized low density lipoprotein-induced injuries via suppression of LOX-1 and induction of eNOS. Canadian Journal of Physiology and Pharmacology, 2014, 92(1): 299-306.

 

已带教浙江工业大学，温州医科大学，浙江中医药大学，锦州医科大学硕士研究生13人